- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Undervalued based on future growth
Hong Kong Pharmaceuticals & Biotech Undervalued based on future growth
Results
4
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
4 companies
China Resources Pharmaceutical Group
Market Cap: HK$30.7b
An investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally.
3320
HK$4.89
7D
-1.8%
1Y
-14.1%
Tong Ren Tang Technologies
Market Cap: HK$6.0b
Produces and distributes Chinese medicine products in Mainland China and Hong Kong.
1666
HK$4.65
7D
0.2%
1Y
-16.1%
Essex Bio-Technology
Market Cap: HK$2.5b
An investment holding company, develops, manufactures, and sells biologic drugs in China, Hong Kong, and internationally.
1061
HK$4.42
7D
2.8%
1Y
70.0%
JBM (Healthcare)
Market Cap: HK$2.3b
An investment holding company, engages in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products in Hong Kong, Macau, Mainland China, and internationally.
2161
HK$2.86
7D
-3.4%
1Y
121.7%